Table 1.

Summary of trials.

Trial	Total (N)	Year	Author	Duration	Drug	Primary endpoint	Secondary endpoint	Results
DAPA HF	4744	2019	McMurray et al.	18.2 months	Dapagliflozin	Composite of worsening heart failure and death from cardiovascular causes	Cardiovascular death, heart failure hospitalization, changes in KCCQ, worsening renal function, death from any case	Primary outcome occurred in 386 of 2373 patients (16.3 %) in the dapagliflozin group and in 502 of 2371 patients (21.2 %) in the placebo group
EMPEROR Reduced	3730	2020	Packer et al.	16 months	Empagliflozin	Composite of cardiovascular death and hospitalization for heart failure	Occurrence of all adjudicated hospitalization for heart failure and rate of decline in estimated GFR	Primary outcome event occurred in 361 of 1863 patients (19.4 %) in the empagliflozin group and in 462 of 1867 patients (24.7 %) in the placebo group
EMPEROR Preserved	5988	2021	Anker et al.	26.2 months	Empagliflozin	Composite of cardiovascular death and hospitalization for heart failure	Occurrence of all adjudicated hospitalization for heart failure and rate of decline in estimated GFR	Primary outcome event occurred in 415 of 2997 patients (13.8 %) in the empagliflozin group and in 511 of 2991 patients (17.1 %) in the placebo group
SOLOIST WHF	1222	2021	Bhatt et al.	9.0 months	Sotagliflozin	Total number of deaths from cardiovascular causes, hospitalizations and urgent visits for heart failure	Total number of hospitalizations and urgent visits for heart failure, incidence of death from CV and any cause, total number of deaths from CV cause, nonfatal MI, nonfatal stroke, chance in KCCQ, events of HF during hospitalization	Primary outcome occurred in 245 of 608 patients in the sotagliflozin group and in 355 of 614 patients in the placebo group.
DELIVER	6263	2022	Solomon et al.	27 months	Dapagliflozin	Composite of worsening heart failure or Cardiovascular death	Total number of worsening heart failure events and cardiovascular deaths, the change from baseline in the total symptom score on the KCCQ scores, cardiovascular death, death from any cause	Primary outcome occurred in 512 of 3131 patients (16.4 %) in the dapagliflozin group and in 610 of 3132 patients (19.5 %) in the placebo group.

Abbreviations:

DAPA HF = Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; EMPEROR Reduced = Empagliflozin in Heart Failure with a Reduced Ejection Fraction; EMPEROR Preserved = Empagliflozin in Heart Failure with a Preserved Ejection Fraction; SOLOIST WHF = Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure; DELIVER = Dapagliflozin in Heart Failure with mildly reduced or preserved ejection fraction; KCCQ = Kansas City Cardiomyopathy Questionnaire

CV = Cardiovascular; GFR = Glomerular filtration rate.